HomeCompareMANZF vs PFE

MANZF vs PFE: Dividend Comparison 2026

MANZF yields 3544.84% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MANZF wins by $2243956534372.28M in total portfolio value
10 years
MANZF
MANZF
● Live price
3544.84%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2243956534372.33M
Annual income
$2,125,978,866,736,018,400.00
Full MANZF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MANZF vs PFE

📍 MANZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMANZFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MANZF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MANZF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MANZF
Annual income on $10K today (after 15% tax)
$301,311.59/yr
After 10yr DRIP, annual income (after tax)
$1,807,082,036,725,615,600.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MANZF beats the other by $1,807,082,036,725,593,300.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MANZF + PFE for your $10,000?

MANZF: 50%PFE: 50%
100% PFE50/50100% MANZF
Portfolio after 10yr
$1121978267186.19M
Annual income
$1,062,989,433,368,022,400.00/yr
Blended yield
94.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MANZF
No analyst data
Altman Z
0.7
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MANZF buys
0
PFE buys
0
No recent congressional trades found for MANZF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMANZFPFE
Forward yield3544.84%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$2243956534372.33M$49.6K
Annual income after 10y$2,125,978,866,736,018,400.00$26,258.71
Total dividends collected$2235866701905.02M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MANZF vs PFE ($10,000, DRIP)

YearMANZF PortfolioMANZF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$365,184$354,484.23$9,153$693.39+$356.0KMANZF
2$12,489,069$12,098,322.18$8,593$849.25+$12.48MMANZF
3$400,050,181$386,686,877.21$8,336$1,066.78+$400.04MMANZF
4$12,004,094,591$11,576,040,896.75$8,437$1,384.80+$12004.09MMANZF
5$337,476,295,012$324,631,913,799.99$9,013$1,875.40+$337476.29MMANZF
6$8,890,554,943,959$8,529,455,308,295.72$10,306$2,680.72+$8890554.93MMANZF
7$219,514,742,507,524$210,001,848,717,488.40$12,820$4,101.38+$219514742.49MMANZF
8$5,080,777,592,505,851$4,845,896,818,022,800.00$17,673$6,826.70+$5080777592.49MMANZF
9$110,259,502,463,840,940$104,823,070,439,859,660.00$27,543$12,591.86+$110259502463.81MMANZF
10$2,243,956,534,372,328,400$2,125,978,866,736,018,400.00$49,560$26,258.71+$2243956534372.28MMANZF

MANZF vs PFE: Complete Analysis 2026

MANZFStock

Manz AG engages in the manufacture and sale of high-tech equipment in Germany, the United States, Taiwan, rest of Europe, China, and internationally. The company operates in five segments: Solar, Electronics, Energy Storage, Contract Manufacturing, and Service. The Solar segment provides system solutions for thin-film solar modules and CIGS thin-film technology. The Electronics segment offers production, assembly, and handling systems for the manufacture of flat screen displays, touch sensors, printed circuit boards, chip carriers, smartphones, tablet computers, laptops, wearables, and other consumer electronics; and automated assembly solutions for the automotive industry. The Energy Storage segment offers production, assembly, and handling equipment for lithium-ion battery cells, modules, and systems, as well as for capacitors for the manufacture of consumer electronics, power electronics, and other components of electrical powertrain. The Contract Manufacturing segment provides contract manufacturing services for equipment manufacturing, parts production, and assembly works for range of industries. The Service segment offers after-sales services, such as repair and maintenance, or conversion and upgrade services for machines and assemblies. Manz AG also provides simulation and factory planning, process and prototype development, and customer training services. The company was formerly known as Manz Automation AG and changed its name to Manz AG in June 2011. Manz AG was founded in 1987 and is based in Reutlingen, Germany.

Full MANZF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MANZF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MANZF vs SCHDMANZF vs JEPIMANZF vs OMANZF vs KOMANZF vs MAINMANZF vs JNJMANZF vs MRKMANZF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.